130
Participants
Start Date
February 1, 2021
Primary Completion Date
May 30, 2022
Study Completion Date
May 2, 2023
UC-MSC
UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
Anti-CD25 mAb
Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing
Southern Medical University, China
OTHER
Third Military Medical University
OTHER
Sun Yat-sen University
OTHER
Peking University People's Hospital
OTHER